PedAM
Pediatric Disease Annotations & Medicines
| escherichia coli infections | ||||
| Disease ID | 1353 |
|---|---|
| Disease | escherichia coli infections |
| Definition | Infections with bacteria of the species ESCHERICHIA COLI. |
| Synonym | bacterial infection caused by e. coli bacterial infection due to e. coli bacterial infection due to e. coli, nos coli e infection coli e infections coli e. infection colibacillosis e coli infect e coli infection e coli infections e coli infections, recurrent e. coli infection e. coli infections e.coli infection nec/nos escherichia coli [e. coli] nos escherichia coli infect escherichia coli infection escherichia coli infections [disease/finding] infect e coli infect escherichia coli infection caused by escherichia coli infection caused by escherichia coli (disorder) infection due to escherichia coli infection due to escherichia coli (disorder) infection due to escherichia coli, nos infection, e coli infection, escherichia coli infections e coli infections, e coli infections, escherichia coli other and unspecified e. coli other and unspecified escherichia coli other and unspecified escherichia coli [e. coli] recurrent e. coli infections |
| DOID | |
| UMLS | C0014836 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:7) C0034186 | pyelonephritis | 2 C0017658 | glomerulonephritis | 1 C0272412 | splenic abscess | 1 C0011991 | diarrhea | 1 C0029443 | osteomyelitis | 1 C0027697 | nephritis | 1 C0010692 | cystitis | 1 |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:1) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 1353 |
|---|---|
| Disease | escherichia coli infections |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:8) HP:0000010 | Frequent urinary tract infections | 2 HP:0012330 | Pyelonephritis | 2 HP:0000099 | Glomerular nephritis | 1 HP:0004905 | Vitamin A deficiency | 1 HP:0000123 | Nephritis | 1 HP:0002014 | Diarrhea | 1 HP:0045073 | Serositis | 1 HP:0002754 | Bone infection | 1 |
| Disease ID | 1353 |
|---|---|
| Disease | escherichia coli infections |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:1) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:12) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0014836 | amikacin | D000583 | 37517-28-5 | escherichia coli infections | MESH:D004927 | therapeutic | 16983943 | ||
| C0014836 | ampicillin | D000667 | 69-53-4 | escherichia coli infections | MESH:D004927 | therapeutic | 1107297 | ||
| C0014836 | aztreonam | D001398 | 78110-38-0 | escherichia coli infections | MESH:D004927 | therapeutic | 3909335 | ||
| C0014836 | carbenicillin | D002228 | 4697-36-3 | escherichia coli infections | MESH:D004927 | therapeutic | 1107297 | ||
| C0014836 | cefmetazole | D015311 | 56796-20-4 | escherichia coli infections | MESH:D004927 | therapeutic | 14691658 | ||
| C0014836 | ceftazidime | D002442 | 78439-06-2 | escherichia coli infections | MESH:D004927 | therapeutic | 14691658 | ||
| C0014836 | cephalexin | D002506 | 15686-71-2 | escherichia coli infections | MESH:D004927 | therapeutic | 889204 | ||
| C0014836 | chloramphenicol | D002701 | 56-75-7 | escherichia coli infections | MESH:D004927 | therapeutic | 1107297 | ||
| C0014836 | ciprofloxacin | D002939 | 85721-33-1 | escherichia coli infections | MESH:D004927 | therapeutic | 15764192 | ||
| C0014836 | ertapenem | C446479 | - | escherichia coli infections | MESH:D004927 | therapeutic | 20805395 | ||
| C0014836 | piperacillin | D010878 | 61477-96-1 | escherichia coli infections | MESH:D004927 | therapeutic | 3945861 | ||
| C0014836 | tigecycline | C119092 | - | escherichia coli infections | MESH:D004927 | therapeutic | 20805395 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D004927 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D004927 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D004927 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D004927 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |